On Friday, SunTrust Banks, Inc. (NYSE:STI)’s shares inclined 1.78% to $44.14.
According to a SunTrust Banks, Inc. (STI) survey, more than 17 percent of businesses plan to enter or expand into new international markets within the next five years. For many small and mid-market companies, global trade could lead to raised profits and sustained growth.
The U.S. Department of Commerce found that the U.S. had a record level of goods and services exports in 2014 – the fifth year in a row. To assist companies take advantage of the burgeoning international marketplace, SunTrust offers five strategies to navigate global trade and mitigate the risks involved.
SunTrust Banks, Inc. operates as the holding company for SunTrust Bank that provides various financial services in the United States. The company operates in three segments: Consumer Banking and Private Wealth Administration, Wholesale Banking, and Mortgage Banking. The Consumer Banking and Private Wealth Administration segment offers deposits, home equity lines and loans, credit lines, indirect auto loans, student loans, bank cards, and other lending products, in addition to various services.
Kite Pharma Inc (NASDAQ:KITE)’s shares dropped -3.46% to $58.00.
Kite Pharma, Inc. (KITE) and bluebird bio, Inc. (BLUE) declared that they have reached a partnershipagreement to co-develop and co-commercialize second generation T cell receptor (TCR) product candidates directed against the human papillomavirus type 16 E6 (HPV-16 E6) oncoprotein incorporating gene editing and lentiviral technologies. bluebird bio has a platform comprised of lentiviral gene delivery and gene editing capabilities, with a focus on rare diseases and cancer immunotherapies. Kite has a broad existing pipeline of TCR product candidates and will continue to develop its existing and wholly-owned TCR programs directed against high-risk HPV, which are unaffected by this collaboration, counting HPV-16 E6 TCR, presently in a Phase I study, and HPV-16 E7 TCR. The partnership brings together the powerful technologies and capabilities of these two leading immunotherapy companies.
Under the terms of the agreement, both companies will jointly develop and commercialize second generation TCR product candidates directed against the HPV-16 E6 oncoprotein, incorporating gene editing to efficiently modify certain genes to enhance T cell function. In addition, the companies will explore using lentiviral vectors to optimize delivery of HPV-16 E6 TCRs into patient T cells.
Kite will lead the program in the U.S., and bluebird bio will have the option to lead the program in the European Union. Both companies will share overall costs, counting research and development and sales and marketing expenses, and profits will be equally split between the companies. Additionally, Kite will have a co-promotion option in the European Union, and bluebird will have a co-promotion option in the U.S.
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers.
At the end of Friday’s trade, Juno Therapeutics Inc (NASDAQ:JUNO)‘s shares dipped -1.40% to $39.51.
Juno Therapeutics Inc (JUNO) might not be turning a profit yet, but that’s no problem for CEO Hans Bishop’s personal bottom line.
Bishop is the 11th highest-paid CEO in the country, according to Bloomberg’s Pay Index, a daily ranking of the 100 top-paid executives. His pay package was worth $88.2 million at the end of 2014, Bloomberg stated Thursday, in a combination of salary, stock options and restricted shares. That was worth $7.3 million before Juno’s initial public offering in December.
Juno isn’t the only biotech to show up near the top of the list. CEO pay at Santa Monica, Calif.-based Kite Pharma and Waltham, Mass.-based Radius Health Inc. topped $95 million and $33.5 million, respectively.
Juno and Kite develop immunotherapy treatments for cancer. That’s a field investors have been excited to jump into in recent years. Immunotherapy reprograms a patient’s T cells and then infuses them back into the body, giving the immune system a boost to battle the cancer.
This treatment has been heralded in recent years as a breakthrough alternative to harsher methods, such as chemotherapy and radiation.
In small clinical trials, one of Juno’s drug candidates has achieved a 90 percent remission rate in a type of blood cancer.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Prospect Capital Corporation (NASDAQ:PSEC), ended its Friday’s trading session with 0.68% gain, and closed at $7.40.
Prospect Capital Corporation (PSEC) declared that Prospect offered Intelius Holdings, Inc. (“Intelius”), a portfolio company of H.I.G. Capital (“H.I.G.”), with incremental first lien senior secured floating rate debt to support its planned investment in Classmates, Inc. (“CI”).
Founded in 2003 and headquartered in Bellevue, Washington, Intelius provides information about people, their histories, and their connections to people, places, and organizations. Services offered comprise people search (e.g., finding contact information, residence history, employment, education, and other background information on people of interest), reverse people lookup (by phone number, e-mail, and social network), background checks, and identity theft protection services. Customers can access information through one-time purchases or ongoing subscriptions. Intelius has a robust and proprietary technology platform that gathers over 20 billion public records from a large network of publicly and commercially-accessible sources and assigns such records to more than 250 million unique profiles in the United States.
Prospect Capital Corporation is a business development company. It specializes in middle market, mature, mezzanine finance, later stage, emerging growth, buyouts, recapitalizations, turnaround, growth capital, development, subordinated debt tranches of collateralized loan obligations, cash flow term loans, and bridge transactions. It also makes real estate investments particularly in multi-family residential real estate asset class. The fund makes secured debt, senior debt, unitranche debt, first-lien and second lien, private debt, mezzanine debt, and equity investments in private and microcap public businesses. It typically invests across all industry sectors, with a particular expertise in the energy and industrial sectors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
